bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
bioMérieux S.A. hisse başına yıllık % {var1} temettüye sahiptir ve % {var2} oranında bir getiri sunmaktadır. Temettü yıllık ödenmektedir ve son temettü hariç tarihi Jun 9, 2025 tarihindedir.
Dividend Yield
Yıllık Dividende
Özsermaye Tarihi
0.00%
$1.03
Jun 9, 2025
Ödeme Sıklığı
Ödeme Oranı
Yıllık
0.00%
Dividend History
Özsermaye Tarihi
Nakit Tutarı
Kayıt Tarihi
Ödeme Tarihi
Jun 9, 2025
$0.90
Jun 10, 2025
Jun 11, 2025
Jun 7, 2024
$0.85
Jun 10, 2024
Jun 11, 2024
Jun 6, 2023
$0.85
Jun 7, 2023
Jun 8, 2023
Jun 6, 2022
$0.85
Jun 7, 2022
Jun 8, 2022
Jun 4, 2021
$0.62
Jun 7, 2021
Jun 8, 2021
Jul 14, 2020
$0.19
Jul 15, 2020
Jul 16, 2020
Dividend Grafikleri
BMXMF Kâr Payları
BMXMF Dividend Growth (Yıllık Üstünlük)
Follow-Up Questions
bioMérieux S.A.'in şu anki temettü ödemesi ve yıllık temettüsü nedir?